- Home
- GMAB vs RVTY Comparison
GMAB vs RVTY Comparison
Compare GMAB & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RVTY
- Stock Information
- Founded
- GMAB 1999
- RVTY 1937
- Country
- GMAB Denmark
- RVTY United States
- Employees
- GMAB N/A
- RVTY N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RVTY Biotechnology: Laboratory Analytical Instruments
- Sector
- GMAB Health Care
- RVTY Industrials
- Exchange
- GMAB Nasdaq
- RVTY Nasdaq
- Market Cap
- GMAB 12.1B
- RVTY 13.9B
- IPO Year
- GMAB N/A
- RVTY N/A
- Fundamental
- Price
- GMAB $24.14
- RVTY $117.55
- Analyst Decision
- GMAB Buy
- RVTY Buy
- Analyst Count
- GMAB 9
- RVTY 11
- Target Price
- GMAB $40.71
- RVTY $137.73
- AVG Volume (30 Days)
- GMAB 1.2M
- RVTY 973.2K
- Earning Date
- GMAB 05-01-2025
- RVTY 04-28-2025
- Dividend Yield
- GMAB N/A
- RVTY 0.24%
- EPS Growth
- GMAB 83.82
- RVTY N/A
- EPS
- GMAB 16.85
- RVTY 2.20
- Revenue
- GMAB $2,988,286,182.00
- RVTY $2,755,026,000.00
- Revenue This Year
- GMAB $19.59
- RVTY $4.83
- Revenue Next Year
- GMAB $14.50
- RVTY $6.20
- P/E Ratio
- GMAB $14.08
- RVTY $51.11
- Revenue Growth
- GMAB 30.67
- RVTY 0.16
- 52 Week Low
- GMAB $18.64
- RVTY $97.32
- 52 Week High
- GMAB $31.88
- RVTY $129.50
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- RVTY 55.51
- Support Level
- GMAB $23.63
- RVTY $106.61
- Resistance Level
- GMAB $24.11
- RVTY $113.06
- Average True Range (ATR)
- GMAB 0.37
- RVTY 3.53
- MACD
- GMAB 0.22
- RVTY 0.30
- Stochastic Oscillator
- GMAB 93.88
- RVTY 93.94
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RVTY Revvity Inc.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.